Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cel-Sci Corporation (CVM : AMEX)
 
 • Company Description   
CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.13 Daily Weekly Monthly
20 Day Moving Average: 750,934 shares
Shares Outstanding: 43.33 (millions)
Market Capitalization: $135.61 (millions)
Beta: 2.17
52 Week High: $27.28
52 Week Low: $2.49
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.26% 11.20%
12 Week -47.31% -42.07%
Year To Date -55.92% -46.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
8229 BOONE BLVD SUITE 802 .
-
VIENNA,VA 22182
USA
ph: 703-506-9460
fax: 703-506-9471
gdewindt@cel-sci.com None
 
 • General Corporate Information   
Officers
Geert R. Kersten - Chief Executive Officer
Peter Young - Director
Bruno Baillavoine - Director
Robert Watson - Director
Robert Watson - Director

Peer Information
Cel-Sci Corporation (CORR.)
Cel-Sci Corporation (RSPI)
Cel-Sci Corporation (CGXP)
Cel-Sci Corporation (BGEN)
Cel-Sci Corporation (GTBP)
Cel-Sci Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 150837607
SIC: 2836
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 43.33
Most Recent Split Date: 6.00 (0.04:1)
Beta: 2.17
Market Capitalization: $135.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.00
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -15.00%
vs. Previous Quarter: -15.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -67.69
12/31/21 - -69.91
09/30/21 - -77.18
ROA
03/31/22 - -49.79
12/31/21 - -50.35
09/30/21 - -53.13
Current Ratio
03/31/22 - 8.33
12/31/21 - 12.56
09/30/21 - 11.50
Quick Ratio
03/31/22 - -
12/31/21 - 11.94
09/30/21 - 10.99
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.04
12/31/21 - 1.19
09/30/21 - 1.31
Inventory Turnover
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Equity
03/31/22 - 0.28
12/31/21 - 0.25
09/30/21 - 0.23
Debt-to-Capital
03/31/22 - 21.68
12/31/21 - 20.05
09/30/21 - 18.99
 

Powered by Zacks Investment Research ©